Groupe Francophone des Myelodysplasies – Developmental Therapeutics Review – Q4 2010

Date: December 1, 2010
Pages: 28
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: GE57E9A1397EN
Leaflet:

Download PDF Leaflet

Groupe Francophone des Myelodysplasies – Developmental Therapeutics Review – Q4 2010
Groupe Francophone des Myelodysplasies – Developmental Therapeutics Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Groupe Francophone des Myelodysplasies – Developmental Therapeutics Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Groupe Francophone des Myelodysplasies – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Groupe Francophone des Myelodysplasies human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Groupe Francophone des Myelodysplasies with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Groupe Francophone des Myelodysplasies’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Groupe Francophone des Myelodysplasies’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Groupe Francophone des Myelodysplasies in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Groupe Francophone des Myelodysplasies’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Groupe Francophone des Myelodysplasies.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Groupe Francophone des Myelodysplasies and identify potential opportunities in those areas.
Groupe Francophone des Myelodysplasies Snapshot
Key Information
Key Facts
Groupe Francophone des Myelodysplasies – Research and Development Overview
Key Therapeutic Areas
Groupe Francophone des Myelodysplasies – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Groupe Francophone des Myelodysplasies – Pipeline Products Glance
Groupe Francophone des Myelodysplasies Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Groupe Francophone des Myelodysplasies – Drug Profiles
CC-5103 + DNR + AraC
  Product Description
  Mechanism of Action
  R&D Progress
Clofarabine for Myelodysplastic Syndrome
  Product Description
  Mechanism of Action
  R&D Progress
Decitabine
  Product Description
  Mechanism of Action
  R&D Progress
Lenalidomide
  Product Description
  Mechanism of Action
  R&D Progress
Neorecormon + All Trans Retinoic Acid
  Product Description
  Mechanism of Action
  R&D Progress
Vorinostat + Cytarabine
  Product Description
  Mechanism of Action
  R&D Progress
Groupe Francophone des Myelodysplasies – Pipeline Analysis
Groupe Francophone des Myelodysplasies – Pipeline Products by Therapeutic Class
Groupe Francophone des Myelodysplasies Pipeline Products By Target
Groupe Francophone des Myelodysplasies – Pipeline Products by Route of Administration
Groupe Francophone des Myelodysplasies – Pipeline Products by Molecule Type
Groupe Francophone des Myelodysplasies - Dormant Projects
Groupe Francophone des Myelodysplasies – Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 28

LIST OF TABLES

Groupe Francophone des Myelodysplasies – Pipeline by Therapy Area and Indication, 2010
Groupe Francophone des Myelodysplasies – Pipeline by Stage of Development, 2010
Groupe Francophone des Myelodysplasies – Monotherapy Products in Pipeline, 2010
Groupe Francophone des Myelodysplasies – Combination Treatment Modalities in Pipeline, 2010
Groupe Francophone des Myelodysplasies - Phase II, 2010
Groupe Francophone des Myelodysplasies - Pipeline By Therapeutic Class, 2010
Groupe Francophone des Myelodysplasies - Pipeline By Target, 2010
Groupe Francophone des Myelodysplasies – Pipeline By Route of Administration, 2010
Groupe Francophone des Myelodysplasies – Pipeline By Molecule Type, 2010
Groupe Francophone des Myelodysplasies - Dormant Developmental Projects, 2010 25

LIST OF FIGURES

Groupe Francophone des Myelodysplasies – Pipeline by Therapy Area and Indication, 2010
Groupe Francophone des Myelodysplasies – Pipeline by Stage of Development, 2010
Groupe Francophone des Myelodysplasies – Monotherapy Products in Pipeline, 2010
Groupe Francophone des Myelodysplasies – Combination Treatment Modalities in Pipeline, 2010
Groupe Francophone des Myelodysplasies – Pipeline By Therapeutic Class, 2010
Groupe Francophone des Myelodysplasies - Pipeline By Target, 2010
Groupe Francophone des Myelodysplasies – Pipeline By Route of Administration, 2010
Groupe Francophone des Myelodysplasies – Pipeline By Molecule Type, 2010 24

Ask Your Question

Groupe Francophone des Myelodysplasies – Developmental Therapeutics Review – Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: